
{
  "Company Overview": {
    "Name": "Gujarat Themis Biosyn Ltd",
    "Sector": "Pharmaceuticals",
    "Industry": "Pharmaceuticals - Indian - Bulk Drugs",
    "Business Description": "Manufactures and sells finished Active Pharmaceutical Ingredients products by fermentation process.  It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary). GTBL entered into Technical & Financial collaboration with Yuhan Corporation, South Korea, and became India’s first Company to start commercial production of the Anti-tuberculosis drug Rifampicin.",
    "Market Position": "India’s first Company to start commercial production of the Anti-tuberculosis drug Rifampicin."
  },
  "Financial Metrics": {
    "Market Cap": "₹ 3,354 Cr.",
    "Current Price": "₹ 308",
    "High / Low": "₹ 390 / ₹ 128",
    "Stock P/E": 63.6,
    "Book Value": "₹ 20.5",
    "Dividend Yield": "0.22 %",
    "ROCE": "45.0 %",
    "ROE": "33.8 %",
    "Face Value": "₹ 1.00",
    "Debt-to-Equity Ratio": null //Not explicitly provided, needs further parsing or external data
  },
  "Performance Trends": {
    "Quarterly Results": {
      "Sales": [35, 19, 29, 45, 48, 28, 28, 50, 40, 39, 42, 39, 35],
      "Expenses": [17, 9, 16, 22, 23, 16, 13, 26, 23, 21, 21, 20, 19],
      "Operating Profit": [18, 10, 13, 23, 24, 12, 14, 24, 17, 17, 21, 19, 15],
      "OPM %": ["53%", "53%", "45%", "51%", "51%", "43%", "52%", "47%", "42%", "45%", "50%", "48%", "44%"],
      "Other Income": [1, 1, 2, 1, 1, 2, 2, 1, 1, 1, 1, 1, 0],
      "Interest": [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0],
      "Depreciation": [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1],
      "Profit before tax": [18, 10, 14, 24, 25, 13, 16, 24, 17, 18, 21, 18, 14],
      "Tax %": ["25%", "26%", "29%", "25%", "26%", "26%", "25%", "26%", "26%", "26%", "24%", "26%", "26%"],
      "Net Profit": [14, 7, 10, 18, 19, 10, 12, 18, 13, 13, 16, 13, 11],
      "EPS in Rs": [1.27, 0.65, 0.90, 1.63, 1.72, 0.90, 1.07, 1.63, 1.15, 1.19, 1.46, 1.21, 0.97]
    },
    "Annual Results": {
      "Sales": [28, 30, 31, 33, 36, 39, 41, 85, 91, 115, 148, 170, 154],
      "Expenses": [25, 24, 25, 27, 30, 33, 34, 53, 50, 57, 75, 91, 82],
      "Operating Profit": [3, 6, 7, 6, 6, 6, 7, 32, 40, 58, 74, 79, 72],
      "OPM %": ["11%", "21%", "21%", "19%", "17%", "16%", "18%", "37%", "45%", "51%", "50%", "46%", "47%"],
      "Other Income": [0, 0, 0, 0, 0, 0, 2, 2, 3, 4, 7, 4, 3],
      "Interest": [1, 1, 0, 0, 0, 0, 0, 1, 1, 1, 0, 0, 0],
      "Depreciation": [1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 3, 4, 4],
      "Profit before tax": [1, 5, 5, 5, 5, 5, 8, 31, 41, 59, 77, 79, 71],
      "Tax %": ["0%", "0%", "0%", "0%", "10%", "20%", "22%", "24%", "26%", "26%", "25%", "25%", "25%"],
      "Net Profit": [1, 5, 5, 5, 4, 4, 6, 24, 30, 44, 58, 59, 53],
      "EPS in Rs": [0.10, 0.42, 0.42, 0.42, 0.40, 0.36, 0.59, 2.17, 2.77, 4.00, 5.32, 5.43, 4.83]
    }
  },
  "Ratios": {
    "Growth Ratios": {
      "Compounded Sales Growth": {
        "10 Years": "19%",
        "5 Years": "33%",
        "3 Years": "23%",
        "TTM": "6%"
      },
      "Compounded Profit Growth": {
        "10 Years": "29%",
        "5 Years": "56%",
        "3 Years": "25%",
        "TTM": "2%"
      },
      "Stock Price CAGR": {
        "10 Years": "59%",
        "5 Years": "115%",
        "3 Years": "70%",
        "1 Year": "139%"
      }
    },
    "Liquidity Ratios": null, //Not explicitly provided
    "Profitability Ratios": {
      "ROE": {
        "10 Years": null,
        "5 Years": "45%",
        "3 Years": "41%",
        "Last Year": "34%"
      },
      "ROCE": {
          "Mar 2013": "208%",
          "Mar 2014": "121%",
          "Mar 2015": "81%",
          "Mar 2016": "55%",
          "Mar 2017": "42%",
          "Mar 2018": "45%",
          "Mar 2019": "84%",
          "Mar 2020": "67%",
          "Mar 2021": "67%",
          "Mar 2022": "61%",
          "Mar 2023": "45%"
      }
    },
    "Valuation Ratios": {
      "P/E": 63.6,
      "Price to Book": null //Not explicitly stated, needs calculation
    },
    "Other Ratios": {
      "Debtor Days": [37, 15, 28, 24, 71, 26, 52, 87, 59, 80, 44, 58],
      "Inventory Days": [58, 78, 194, 144, 255, 201, 33],
      "Days Payable": [1498, 947, 240, 84, 145, 131, 99],
      "Cash Conversion Cycle": [-1403, 15, 28, 24, 71, -844, 52, 41, 119, 189, 114, -7],
      "Working Capital Days": [-172, -128, -76, -69, -30, -43, -58, 42, 96, 158, 92, 53]
    }
  },
  "Peer Comparison": {
    "Peers": [
      {"Name": "Divi's Lab.", "CMP": 5846.75, "P/E": 84.54, "Mar Cap": 155212.84, "Div Yld": 0.51, "NP Qtr": 510.00, "Qtr Profit Var": 46.55, "Sales Qtr": 2338.00, "Qtr Sales Var": 22.47, "ROCE": 16.48},
      {"Name": "Neuland Labs.", "CMP": 13891.15, "P/E": 67.48, "Mar Cap": 17822.19, "Div Yld": 0.10, "NP Qtr": 32.84, "Qtr Profit Var": -63.20, "Sales Qtr": 310.84, "Qtr Sales Var": -25.59, "ROCE": 33.26},
      {"Name": "Jubilant Pharmo", "CMP": 1061.60, "P/E": 59.42, "Mar Cap": 16911.29, "Div Yld": 0.47, "NP Qtr": 102.50, "Qtr Profit Var": 81.29, "Sales Qtr": 1752.30, "Qtr Sales Var": 4.28, "ROCE": 6.74},
      {"Name": "Ami Organics", "CMP": 2120.40, "P/E": 92.93, "Mar Cap": 8679.74, "Div Yld": 0.14, "NP Qtr": 37.56, "Qtr Profit Var": 387.34, "Sales Qtr": 246.73, "Qtr Sales Var": 43.15, "ROCE": 15.99},
      {"Name": "Hikal", "CMP": 378.40, "P/E": 63.53, "Mar Cap": 4665.70, "Div Yld": 0.32, "NP Qtr": 18.30, "Qtr Profit Var": 45.58, "Sales Qtr": 452.90, "Qtr Sales Var": 4.14, "ROCE": 7.79},
      {"Name": "Aarti Drugs", "CMP": 428.25, "P/E": 31.48, "Mar Cap": 3937.12, "Div Yld": 0.23, "NP Qtr": 30.39, "Qtr Profit Var": -12.12, "Sales Qtr": 543.09, "Qtr Sales Var": -5.96, "ROCE": 13.68}
    ],
    "Median": {
      "CMP": 276.15,
      "P/E": 33.95,
      "Mar Cap": 409.76,
      "Div Yld": 0.12,
      "NP Qtr": 6.98,
      "Qtr Profit Var": 36.86,
      "Sales Qtr": 76.58,
      "Qtr Sales Var": 14.86,
      "ROCE": 13.88
    }
  },
  "Other Insights": {
    "Pros": [
      "Company is almost debt free.",
      "Company has delivered good profit growth of 56.0% CAGR over last 5 years",
      "Company has a good return on equity (ROE) track record: 3 Years ROE 41.4%",
      "Company has been maintaining a healthy dividend payout of 20.8%",
      "Company's working capital requirements have reduced from 101 days to 53.3 days"
    ],
    "Cons": [
      "Stock is trading at 15.0 times its book value",
      "Promoter holding has decreased over last 3 years: -4.13%"
    ],
    "Disclaimer": "The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis." ,
    "Shareholding Pattern Notes": "* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards. Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes. Click on the line-items to see the names of individual entities."
  },
  "Shareholding Pattern": {
    "Quarterly": {
      "Promoters": [74.99, 74.99, 74.99, 75.00, 75.00, 75.00, 75.00, 75.00, 70.87, 70.87, 70.87, 70.87],
      "FIIs": [0.00, 0.00, 0.00, 0.00, 0.01, 0.01, 0.01, 0.01, 0.86, 1.05, 1.44, 1.49],
      "DIIs": [0.31, 0.31, 0.31, 0.03, 0.03, 0.03, 0.03, 0.03, 0.04, 0.82, 1.18, 1.17],
      "Public": [24.70, 24.70, 24.69, 24.98, 24.96, 24.95, 24.95, 24.96, 28.23, 27.26, 26.52, 26.47]
    },
    "Yearly": {
      "Promoters": [74.99, 74.99, 74.99, 74.99, 74.99, 74.99, 75.00, 70.87, 70.87],
      "FIIs": [0.00, 0.00, 0.00, 0.00, 0.00, 0.00, 0.01, 1.05, 1.49],
      "DIIs": [0.03, 0.03, 0.03, 0.03, 0.03, 0.31, 0.03, 0.82, 1.17],
      "Public": [24.97, 24.97, 24.97, 24.97, 24.97, 24.70, 24.95, 27.26, 26.47]
    }
  }
}
